Integrated Biopharma INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQX
Integrated BioPharma reports a net loss of $0.8 million for the third quarter of 2026 amid declining sales and high customer concentration.
OQX
Integrated BioPharma, Inc. reported a net loss for the quarter and six months ended December 31, 2025, driven by significant sales decreases and margin erosion.
OQX
Integrated BioPharma, Inc. reported a significant drop in net income and sales for the first quarter of fiscal year 2026, primarily due to decreased volumes from major contract manufacturing customers.
OQX
Integrated BioPharma reports increased sales and profitability for the third quarter of 2025, driven by growth in both its Contract Manufacturing and Other Nutraceutical Businesses segments.
OQX
Integrated BioPharma, Inc. reports a 7% increase in net sales and a significant improvement in operating income for the six months ended December 31, 2024, compared to the same period in 2023.
OQX
10-Q: Integrated BioPharma Reports Profitable Quarter Amidst Supply Chain and Inflationary Pressures
Integrated BioPharma, Inc. reports a profitable quarter with increased sales and improved margins, despite ongoing challenges from inflation and supply chain issues.
OQX
Integrated BioPharma's Q3 2024 results show a slight decrease in net sales and a shift from operating income to a loss, while navigating customer concentration and economic challenges.
OQX
Integrated BioPharma's latest quarterly report shows a slight decrease in net sales and an increased operating loss compared to the same period last year.